key: cord-0957216-a9587gd4
authors: Pillet, Stéphane; Arunachalam, Prabhu S.; Andreani, Guadalupe; Golden, Nadia; Fontenot, Jane; Aye, Pyone; Röltgen, Katharina; Lehmick, Gabrielle; Dubé, Charlotte; Gobeil, Philipe; Trépanier, Sonia; Charland, Nathalie; D’Aoust, Marc-André; Russell-Lodrigue, Kasi; Blair, Robert V.; Boyd, Scott; Bohm, Rudolph B.; Rappaport, Jay; Villinger, François; Ward, Brian J.; Pulendran, Bali; Landry, Nathalie
title: Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates
date: 2021-05-15
journal: bioRxiv
DOI: 10.1101/2021.05.15.444262
sha: 36544af2289b75587ac905c9ecdacac6d1966fa7
doc_id: 957216
cord_uid: a9587gd4

Although antivirals are important tools to control the SARS-CoV-2 infection, effective vaccines are essential to control the current pandemic. Plant-derived virus-like particle (VLP) vaccine candidates have previously demonstrated immunogenicity and efficacy against influenza. Here we report the immunogenicity and protection induced in macaques by intramuscular injections of VLP bearing SARS-CoV-2 spike protein (CoVLP) vaccine candidate formulated with or without Adjuvant System 03 (AS03) or cytosine phosphoguanine (CpG) 1018. Although a single dose of unadjuvanted CoVLP vaccine candidate stimulated humoral and cell-mediated immune responses, booster immunization (at 28 days after prime) and adjuvants significantly improved both responses with a higher immunogenicity and protection provided by AS03 adjuvanted CoVLP. Fifteen microgram CoVLP adjuvanted with AS03 induced a balanced IL-2 driven response along with IL-4 expression in CD4 T cells and mobilization of CD4 follicular helper cells (Tfh). Animals were challenged by multiple routes (i.e. intratracheal, intranasal and ocular) with a total viral dose of 106 plaque forming units of SARS-CoV-2. Lower viral replication in nasal swabs and broncho-alveolar lavage (BAL) as well as fewer SARS-CoV-2 infected cells and immune cell infiltrates in the lungs concomitant with reduced levels of pro-inflammatory cytokines and chemotactic factors in BAL were observed in the animals immunized with CoVLP adjuvanted with AS03. No clinical, pathologic or virologic evidences of vaccine associated enhanced disease (VAED) were observed in vaccinated animals. CoVLP adjuvanted with AS03 was therefore selected for vaccine development and clinical trials.

In December 2019, a series of severe atypical respiratory disease cases occurred in Wuhan China, and a novel coronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was rapidly identified as the causative agent of coronavirus disease 2019 . SARS-CoV-2 virions consist of a helical nucleocapsid, formed by association of nucleocapsid (N) phosphoproteins with viral genomic RNA that is surrounded by a lipid bilayer, into which three structural proteins are inserted: the spike move to lipid rafts of the plasma membrane where they spontaneously assemble into virus-like particles (VLPs) that 'bud' off the surface of the plant cell. The S proteins in CoVLP are in a stabilized, prefusion conformation that resembles the native structure seen on SARS-CoV-2 virions. The prefusion form of S protein is preferred as a vaccine antigen since it contains several epitopes in the RBD that are primary targets for neutralising antibodies 6 . Moreover, previous study on the MERS S protein revealed that the prefusion state also resulted in a more potent immunogen with dose-sparing properties compared to protein made with the original wild-type sequence 7 . In a pandemic situation, large numbers of vaccine doses are required to protect the maximum number of people worldwide. Dosesparing adjuvants are often used to maximize the number of vaccine doses available, i.e. to reduce the amount of antigen needed to elicit a robust and persistent immune response 8 .

Two adjuvants with demonstrated potential for dose-sparing were included in the current study: the cytidine-phospho-guanosine (CpG)-containing immunostimulatory oligodeoxynucleotide sequence 1018 (CpG 1018: Dynavax) and the α-tocopherol- The Adjuvanted System AS03 initiates a transient innate immune response at the injection site and draining lymph node in animal models 11 and in human peripheral blood [12] [13] [14] . That innate immune response potentiates and shapes the adaptive immune response to the vaccine antigen including both antibody and T-cell responses, resulting in increased response magnitude, breadth, durability and antibody avidity [15] [16] [17] . AS03 has been used in the licensed pandemic A/H1N1pdm09 influenza vaccines Arepanrix H1N1 (in Canada), Q Pan H5N1 (in the USA) and Pandemrix (in Europe), of which 90 million doses have been administered worldwide, as well as in other licensed (Q Pan H5N1 in the USA) or vaccine candidates 18 . The present study assessed the safety, immunogenicity, and protective efficacy of two doses, 28-days apart, of a plant-produced virus-like-particle vaccine candidate for COVID-19 in rhesus macaques. 

The full-length S glycoprotein of SARS-CoV-2, strain hCoV-19/USA/CA2/2020, corresponding in sequence to nucleotides 21563 to 25384 from EPI_ISL_406036 in GISAID database (https://www.gisaid.org/) was transiently expressed in Nicotiana benthamiana plants using a similar strategy previously described to produce influenza vaccine candidate 5 . The S protein was modified with R667G, R668S and R670S substitutions at the S1/S2 cleavage site to increase stability, and K971P and V972P substitutions to stabilize the protein in the prefusion conformation 19 . The signal peptide was replaced with a plant gene signal peptide and the transmembrane domain (TM) and cytoplasmic tail (CT) of S protein were also replaced with TM/CT from Influenza hemagglutinin H5 from A/Indonesia/5/2005 to increase VLP assembly and budding. The self-assembled VLPs bearing S protein trimers were isolated from the plant matrix and subsequently purified using a process similar to that described for the influenza vaccine candidates 5 

Male Indian rhesus macaques were immunized intramuscularly (IM) with one (at day 0, 

Clinical observations, including general behavior, visible signs of disease (reduced appetite; hunched posture; pale appearance; dehydration) were performed daily before challenge.

Body temperature and weight were measured for all animals at each scheduled anesthetic event, i.e. on D0 (before immunization), D1, D3 and D7 after the first immunization for all groups and on D28 (before second immunization), D29, D32 and D35 for groups 5 to 8.

Body temperature and weight changes are presented as relative to the baseline before each immunization.

The injection sites were monitored for 7 days after each immunization using standard measures including upper arm circumference, lymph node enlargement (size, mobility, number), warmth, erythema, local lesions (ulcers, abscess) or other abnormalities. Each of these parameters was graded throughout the study by the same experienced investigator blind to group assignment (0 = absent, 1 = mild, 2 = moderate, 3 = severe). Upper arm circumference and lymph node enlargement were manually assessed at scheduled anesthetic events, up to 7 days after injection (D0, D1, D3 and D7 for all groups and D28 (before dosing), D29, D32 and D35 for groups 5 to 8).

Routine hematologic (e.g. hematocrit, hemoglobin level, and white blood cell count) and biochemical analyses (e.g. blood urea nitrogen, serum creatinine, total protein, albumin, aspartate aminotransferase, gamma-glutamyl transpeptidase, and C-reactive protein

[CRP]) were performed on whole blood samples from all animals. Blood samples were collected before immunization (baseline) and on D1, D3 and D7 for the One-dose cohort; the day of the second immunization (before dosing), D29, D32 and D35 for the Two-dose cohort.

Serum samples from all animals were collected at baseline, D21 and D49. NAb titers were measured by laboratory staff blind to group allocation at Battelle Biomedical Research Center (OH, USA) using a SARS-CoV-2 microneutralization (MN) assay with an in situ ELISA readout against SARS-CoV-2 NP. Briefly, serum samples were incubated with SARS-CoV-2 WA 1/2020 isolate at 37.0±2℃ and 5.0±2% CO2 for 60±5 minutes. The serum/virus mixture was then transferred to previously seeded VERO E6 cell monolayers and incubated for 40 to 46 hours after which the inoculum was removed and plates were rinsed with Hank`s Balanced Salt Solution (HBSS) prior to fixation with 80% acetone.

Following fixation, an in situ ELISA was performed for the detection of SARS-CoV-2 NP antigen using an anti-SARS-COV-2, MERS, SARS-CoV NP primary antibody (EastCoast Bio; ME, USA) and a Goat Anti-Mouse IgG conjugate antibody (Fitzgerald; MA USA).

Samples were analyzed in duplicate and results are reported as the median of two independent analyses. The final value for each sample is expressed as MN50. Nonresponders (MN50 value <20), if any, were assigned a value of 10. Four negative sera were also included in the optimization process. After washing to remove unbound antibodies, specific RBD-bound IgG, IgA or IgM antibodies were detected by horseradish peroxidase-conjugated goat anti-monkey/human IgG (γ-chain specific, catalog no. 62-8420, Thermo Fisher), IgM (μ-chain specific, catalog no. A6907, Sigma), or IgA 

Antigen-specific T cell responses were measured by intracellular cytokine stain (ICS) assay at baseline, D7 and D21 after the first dose; and D35 and D49 after the second dose. Frozen PBMCs were thawed, counted and resuspended at a density of 1 million live cells/mL in complete RPMI (RPMI supplemented with 10% FBS and antibiotics). The cells were rested overnight at 37°C in CO2 incubator. Next morning, the cells were counted again, resuspended at a density of 15 million/mL in complete RPMI and 100 μL of cell suspension containing 1.5 million cells was added to each well of a 96-well round-bottomed tissue culture plate and stimulated ex vivo with a peptide pool consisting of 15mer peptides overlapping by 11 amino acids spanning the S protein (GenScript, Piscataway, NJ), at a concentration of 1.2 μg/mL of each peptide in the presence of 1 μg/mL anti-CD28. The samples were incubated at 37°C in a CO2 incubators for 2h before addition of 10 μg/mL Brefeldin-A. The cells were incubated for an additional 4h. The cells were washed with PBS and stained with Zombie UV fixable viability dye (BioLegend). The cells were washed with PBS containing 5% FCS, before the addition of surface antibody cocktail (Suppl. Table 2 ). The cells were stained for 20 min at 4°C in 100 μL volume. Subsequently, the cells were washed, fixed and permeabilized with cytofix/cytoperm buffer (BD Biosciences) for 20 minutes. The permeabilized cells were stained with ICS antibody cocktail (Suppl. Table 2 ) for 20 min at room temperature in 1X-perm/wash buffer (BD Biosciences). Cells were then washed twice with perm/wash buffer (BD Biosciences) and once with staining buffer before analysis using BD Symphony Flow Cytometer. All flow cytometry data were analyzed using Flowjo software v10 (TreeStar Inc.).

Animals were infected under anesthesia with viral isolate SARS-CoV-2 USA-WA1/2020 (originally obtained from a patient in Seattle, USA, kindly provided by University of Texas, Medical Branch, Galveston, Texas) as previously described 21, 22 . The virus stock was generated by expansion of a seed stock on Vero E6 cells and titrated by plaque assay on Vero E6 cells. It was deep sequenced and found to contain no polymorphisms at greater than 5% of reads relative to the original patient isolate. The furin cleavage site, a site with frequent culture adaptation in Vero E6 cells, harbored no polymorphisms at greater than 1% of sequence reads in this stock. Animal were challenged by multi-route administration (i.e. 500 µL intratracheal, intranasal (approximately 250 ul on each nares) and conjunctival (10 µL)) with a total viral dose of 10 6 plaque forming units (PFU).

Clinical observations, including state of responsiveness, presence of discharge, skin condition, respiratory condition, food consumption and fecal conditions were performed daily after challenge until termination by laboratory staff blind to group allocation. Animals were individually scored for the severity of these parameters and clinical scores were assigned according to the chart provided in supplementary material (Appendix). Thoracic radiographs were obtained 6, 13 and 20 days post-challenge.

Body temperature, weight, respiratory rate and levels of oxygen saturation (SpO2) were measured for all animals on the challenge day (before virus administration) and on days 6, 13 and 20 post-challenge for all animals. Body temperature, weight and SpO2 changes are presented as relative to challenge day (before infection).

Routine hematologic (e.g. hematocrit, hemoglobin level, and white blood cell count) and biochemical analyses (e.g. blood urea nitrogen, serum creatinine, total protein, albumin, aspartate aminotransferase, gamma-glutamyl transpeptidase, and CRP) were performed on whole blood samples from all animals 6, 13 and 20 days post-challenge.

Tissue (lungs, liver, kidneys, spleen, thymus and heart) samples for routine gross pathology examination were collected from all animals, i.e. 3 animals per group on two occasions, 6 and 20 days post viral infection, with the exception of the CoVLP+AS03 group that received 2 immunizations (group 7) from which 2 animals were euthanized 6 days after infection and 4 animals 20 days after infection. Animals were chosen randomly. (accession MN908947). The reaction master mix was added to the microtiter plates using an X-stream repeating pipette (Eppendorf, Hauppauge, NY) which were then covered with optical film (Thermo Fisher), vortexed, and pulse centrifuged. The RT-qPCR reaction was subjected to RT-qPCR a program of UNG incubation at 25°C for 2 minutes, RT incubation at 50°C for 15 minutes, and an enzyme activation at 95°C for 2 minutes followed by 40 cycles of a denaturing step at 95°C for 3 seconds and annealing at 60°C for 30 seconds. (± 0.5) cycles. Viral copy numbers were determined by plotting Cq values obtained from unknown (i.e. test) samples against Serial tenfold dilutions of an exogenous calibration curves ranging from 10 1 to 10 8 log copy numbers generated from known amounts of in vitro-transcribed ssRNA for interpolation to determine the number of virus copies per mL of initial specimen sample or test dilution, as applicable. The limit of detection of the assay was 10 copies per reaction volume. To control for assay variation, validation of results, IPC quantification consistency, and reagent stability, replicates of a positive control sample also were analyzed in parallel with every set of test samples. Negative control plasma samples were included for processing with every set of test samples to monitor crosscontamination. A non-template control (NTC) was included in all runs to ensure that there was no cross-contamination between reactions. Cytokines were measured using 497 Mesoscale Discovery. IL-16, IL-6, IL-10, IL-8, IL-2,   IL-15, IL- Quickplex 500 SQ120 machine. Values below the limit of detection (LOD) were replaced with 50% of the LOD based on the lowest value of the standard curve for each analyte.

Lung tissues sections were prepared as previously described 21 

None of the vaccine formulations induced any increase of body temperature during the seven days after the first or second immunization. All animals, including those in the Control group, lost weight during that study period after the first immunization, independent of the treatment. No weight loss was observed after the second immunization. After the first immunization, clinical observations were limited to reduced appetite (also seen in the Control group) and loose or soft stool, that occurred concurrently with normal stool. After the second immunization, no clinical signs were observed.

Hematology results did not reveal any safety concern up to 7 days after the first and second immunizations. The CoVLP+AS03 led to a transient mobilization of immune cells in the periphery one day after the first and second doses. This was mainly manifested by an increase of neutrophils and monocytes after the first immunization, and an increase of neutrophils after the second immunization, and was accompanied by a transient CRP signal reflecting the inflammatory reaction upon vaccination with the AS03-adjuvanted CoVLP.

Immune cell mobilization and CRP increase were resolved 3 days after immunization and was not observed with unadjuvanted CoVLP or CoVLP+CpG.

The RBD specific immunoglobulin (Ig) G, IgA and IgM were measured in pre-immune samples and at D14, D21 or D28 after the first immunization as well as 14 and 21 days after the second immunization (D42 and D49 respectively). No statistically significant differences were observed between the RBD specific IgG, IgA or IgM responses at D21 and at D28. Therefore, those two timepoints were combined (Figure 2) . Unadjuvanted

CoVLP induced a significant increase of RBD-specific IgG as early as 14 days after the first immunization ( Figure 2A ) that was maintained at 21-28 days. Both CpG and AS03 significantly increased RBD-specific IgG 14 and 21-28 days after immunization compared to unadjuvanted CoVLP, with a significantly greater impact of AS03 compared to CpG.

All groups benefited from the boost sustaining the higher responses of adjuvanted formulations as compared to unadjuvanted CoVLP after the second dose (Figure 2A) . The superior response for CoVLP+AS03 was maintained at all timepoints after the boost.

Animals immunized with 2 doses of CoVLP+CpG experienced a small, although significant decrease in RBD-specific IgG levels between D42 and D49 (Figure 2A) . Serum RBD-specific IgA responses were similar to RDB-specific IgG responses in intensity and ranking between groups ( Figure 2B ). Titres rose slightly in response to the unadjuvanted CoVLP but only barely reached statistical significance above baseline values after either the first or second dose. Animals that received adjuvanted CoVLP mounted stronger IgA responses that rose significantly at D14 and further increased with the second dose. Again, the IgA responses were consistently highest in the CoVLP+AS03 group at all timepoints.

As observed with IgG, animals immunized with 2 doses of CoVLP+CpG experienced a small but significant decrease in RBD-specific IgA levels between D42 and D49 ( Figure   2B ).

Although RBD-IgM levels remained significantly above baseline at all timepoints in the CoVLP+AS03 group, levels tended to fall in all groups at later times after the first dose and were not greatly influenced by the booster dose ( Figure 2C ), consistent with immunoglobulin class switching and the normal kinetics of IgM production following vaccination. RBD-specific IgM levels also rose in response to vaccination in CoVLP+CpG group but only reached statistical significance transiently at D14 and D21 ( Figure 2C ).

Serum NAb titers were measured at D21 and D49. None of the animals in the CoVLP group mounted a detectable NAb response after the first dose and NAb were detected in only 1/6 animals after the second dose. Among the animals that received adjuvanted vaccine only 2/12 and 3/12 in the CoVLP+CpG and CoVLP+AS03 groups respectively, mounted detectable responses after the first dose ( Figure 2D ). Responses after the second dose were significantly above baseline values in both the CoVLP+CpG and CoVLP+AS03 groups illustrating the significant impact on both adjuvants on the NAb response although levels in the CoVLP+AS03 group after the second dose were significantly higher than in the CoVLP+CpG group.

The cell-mediated immune (CMI) response was measured in PBMC re-stimulated ex vivo with an S protein peptide pool at baseline, 7 and 21 days after the first and the second IM Significant induction of Ag-specific IL-4+ was observed after the boost in all groups, particularly in NHP immunized with CoVLP+AS03 ( Figure 3D ). However, the frequencies of Ag-specific IL-4+ CD4 T cells remained lower than Ag-specific IL-2+ CD4 T cells, even in the AS03 adjuvanted group.

Qualitative differences were observed in the CD4 T cells response elicited by the different vaccine regimens ( Figure 3E&F ). The response induced by CoVLP+AS03 was characterized by the higher frequency of IL-2+ TNF-α+ (IFN-γ-) CD4 T cells and remained relatively consistent with minimal impact of the boost on the relative proportion of the subpopulations based on the expressing of Th1 cytokines ( Figure 3E ).

In contrast, the quality of the Th1 response was strongly impacted by the boost in unadjuvanted CoVLP and CoVLP+CpG characterized by a predominance of monovalent CD4 T cells before boost and emergence of polyfunctionality after the boost. Notably, the relative proportion of triple positive IL-2+ IFN-γ+ TNF-α+ CD4 T cells increased after the second dose of CoVLP+CpG ( Figure 3E ).

The Ag-specific IL-4+ CD4 T cell response was strongly impacted by the boost with CoVLP+AS03 with emergence of IL-4+ IL-21+ CD4 T cells after the second dose ( Figure   3F ). The Th2 response in the CoVLP and CoVLP+CpG groups were characterized by the dominance of monovalent CD40L+ CD4 T cells ( Figure 3F ).

In agreement with previously reported SARS-CoV-2 virus challenge in rhesus macaques, infection only resulted in mild symptoms in the control animals 22, 23 with no significant differences in clinical scores between groups (Suppl. Figure 1) . Animals in all groups CoVLP+CpG and one with 2 doses CoVLP) and 3 control animals (data not shown). A more sensitive PCR assay measuring the N gene product 24 was therefore used to measure viral replication in BAL ( Figure 4B ). In animals immunized with one dose, sg N RNA was not detected in the CoVLP alone group or in the animals that received CoVLP+AS03. Viral replication was observed in BAL from 3/6 (50%) and 2/4 (50%) animals in the CoVLP+CpG and Control groups, respectively ( Figure 4B ). In animals that received two doses, SgRNA was only detected in only 1/6 (16.6%) animal in the CoVLP+AS03 group compared to 5/6 (83.3%) of the animals in the CoVLP alone group, 2/6 (33.3%) in the CoVLP+CpG group and 2/4 Control animals ( Figure 4B ). Neither E nor N gene sgRNA was detected 13 or 20 days after challenge in BAL.

SARS-CoV-2 infected cells and immune cell infiltration were detected by immunohistochemistry (Suppl. Figure 2A&B ) and quantified in lung sections 6 days post-challenge ( Figure 4C ). Compared to the Control group, fewer SARS-CoV-2 infected cells were observed in the lungs of most animals that had received at least 1 dose of CoVLP with or without adjuvant and no SARS-CoV-2 infected cells were detected in the animals immunized with 2 doses of CoVLP+AS03 ( Figure 4C ). The lungs of Control animals were also characterized by the presence of immune cell infiltrates and expansion of the alveolar interstitium and perivascular spaces (Suppl. Figure 2C&D ). While vaccination with one dose of adjuvanted CoVLP had minor impact, immunization with 2 doses of CoVLP strongly reduced the presence of macrophages, neutrophils and T lymphocytes in lungs 6 days after infection ( Figure 5 ). Animals receiving 2 doses of adjuvanted CoVLP had a 3fold reduction in macrophages ( Figure 5A ), a 2-to 4-fold reduction in neutrophils ( Figure   5B ) and a 12-to 20-fold reduction T cell infiltration ( Figure 5C ) compared to Control animals.

The most pronounced differences in cytokine and chemokine profiles in the BAL between treatment groups were observed 6 days post-challenge in the animals infected after 2 vaccine doses ( Figure 6 ) while only limited differences were observed in animals challenged after one dose. In this context, it may be worth noting that the viral loads in nasal swabs from Control animals in the two-dose cohort were generally higher than in the Control group in the one-dose cohort. Although levels varied widely between animals in most groups, the Control animals tended to have the highest mean values for all of the cytokines/chemokines measured. Two doses of either unadjuvanted CoVLP or CoVLP+CpG had relatively little impact on the cytokine/chemokine profile except for lower IL-10 and IL-16 levels compared to the Control group ( Figure 6 ). Although the difference only reached significance for IL-10, the animals that received two doses of CoVLP+AS03 generally had consistently but marginally lower levels of most proinflammatory cytokines and chemotactic factors in the BAL compared to the Control group ( Figure 6) ; a finding consistent with the radiologic and histopathologic evidence of reduced inflammation in the CoVLP+AS03 group.

No safety issues were observed after one or two injections of either the adjuvanted or The observed benefits provided by AS03 on CoVLP were consistent with reported increase immunogenicity and protection 28, 29, 57 . The detailed CMI response reported in the present NHP study, including the possible engagement of Tfh suggest a possible beneficial effect of AS03 on the durability of the immune response. Based on this study and the results from the Phase 1 clinical trial 30 , CoVLP+AS03 was selected for the Phase 2/3 studies. 

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Structure, Function, and Evolution of Coronavirus Spike Proteins

Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition

Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

The spike protein of SARS-CoV--a target for vaccine and therapeutic development

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines

Development of the CpG Adjuvant 1018: A Case Study

Recent progress concerning CpG DNA and its use as a vaccine adjuvant

Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity

Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans

Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signature

AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells

AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses

Safety of AS03-adjuvanted influenza vaccines: A review of the evidence

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates

Acute Respiratory Distress in Aged, SARS-CoV-2-Infected African Green Monkeys but Not Rhesus Macaques

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

The Architecture of SARS-CoV-2 Transcriptome

Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age

Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates. bioRxiv

Phase 1 Randomized Trial of a Plant-Derived Virus-Like Particle Vaccine for Covid-19

A single BNT162b2 mRNA dose elicits antibodies with Fcmediated effector functions and boost pre-existing humoral and T cell responses

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Discrete SARS-CoV-2 antibody titers track with functional humoral stability

Correlates of protection against SARS-CoV-2 in rhesus macaques

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Adaptive immunity to SARS-CoV-2 and COVID-19

Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection

T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice

Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses

Phenotype and function of human T lymphocyte subsets: consensus and issues

Revealing the role of CD4(+) T cells in viral immunity

T-cell quality in memory and protection: implications for vaccine design

Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees

Cytokine diversity in the Th1-dominated human anti-influenza response caused by variable cytokine expression by Th1 cells, and a minor population of uncommitted IL-2+IFNgamma-Thpp cells

Increase in IFNgamma(-)IL-2(+) cells in recent human CD4 T cell responses to 2009 pandemic H1N1 influenza

Follicular helper CD4 T cells (TFH)

T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome

Molecular pathology in the lungs of severe acute respiratory syndrome patients

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

The authors would like to acknowledge Robbert Van Der Most, Cindy Gutzeit, Philipe